

Global RNA Interference (RNAi) Drug Delivery Market Growth 2025-2031

<https://marketpublishers.com/r/G48FF7A28B67EN.html>

Date: January 2024

Pages: 116

Price: US\$ 3,660.00 (Single User License)

ID: G48FF7A28B67EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global RNA Interference (RNAi) Drug Delivery market size is predicted to grow from US\$ million in 2025 to US\$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the "RNA Interference (RNAi) Drug Delivery Industry Forecast" looks at past sales and reviews total world RNA Interference (RNAi) Drug Delivery sales in 2024, providing a comprehensive analysis by region and market sector of projected RNA Interference (RNAi) Drug Delivery sales for

2025 through 2031. With RNA Interference (RNAi) Drug Delivery sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world RNA Interference (RNAi) Drug Delivery industry.

This Insight Report provides a comprehensive analysis of the global RNA Interference (RNAi) Drug Delivery landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNA Interference (RNAi) Drug Delivery portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global RNA Interference (RNAi) Drug Delivery market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Interference (RNAi) Drug Delivery and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Interference (RNAi) Drug Delivery.

This report presents a comprehensive overview, market shares, and growth opportunities of RNA Interference (RNAi) Drug Delivery market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Nanoparticle Drug Delivery Technology

Pulmonary Drug Delivery Technology

Nucleic Acid Drug Delivery Technology

Aptamer Drug Delivery Technology

Segmentation by Application:

Infectious Diseases

Cardiology

Oncology

Neurology

Ophthalmology

Metabolic Disorders

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Metabolic disorders

Alnylam Pharmaceuticals Inc

Merck & Co. Inc

Access Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc

Calondo Pharmaceuticals Inc

Marina Biotech Inc

RXi Pharmaceuticals Corp

Quark Pharmaceuticals Inc

Silence Therapeutics plc

Tacere Therapeutics Inc

PhaseRx Inc

Sirnaomics Inc

Traversa Therapeutics Inc

Key Questions Addressed in this Report

What is the 10-year outlook for the global RNA Interference (RNAi) Drug Delivery market?

What factors are driving RNA Interference (RNAi) Drug Delivery market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do RNA Interference (RNAi) Drug Delivery market opportunities vary by end market size?

How does RNA Interference (RNAi) Drug Delivery break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global RNA Interference (RNAi) Drug Delivery Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for RNA Interference (RNAi) Drug Delivery by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for RNA Interference (RNAi) Drug Delivery by Country/Region, 2020, 2024 & 2031
- 2.2 RNA Interference (RNAi) Drug Delivery Segment by Type
 - 2.2.1 Nanoparticle Drug Delivery Technology
 - 2.2.2 Pulmonary Drug Delivery Technology
 - 2.2.3 Nucleic Acid Drug Delivery Technology
 - 2.2.4 Aptamer Drug Delivery Technology
- 2.3 RNA Interference (RNAi) Drug Delivery Sales by Type
 - 2.3.1 Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2020-2025)
 - 2.3.2 Global RNA Interference (RNAi) Drug Delivery Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global RNA Interference (RNAi) Drug Delivery Sale Price by Type (2020-2025)
- 2.4 RNA Interference (RNAi) Drug Delivery Segment by Application
 - 2.4.1 Infectious Diseases
 - 2.4.2 Cardiology
 - 2.4.3 Oncology
 - 2.4.4 Neurology
 - 2.4.5 Ophthalmology
 - 2.4.6 Metabolic Disorders

2.5 RNA Interference (RNAi) Drug Delivery Sales by Application

2.5.1 Global RNA Interference (RNAi) Drug Delivery Sale Market Share by Application (2020-2025)

2.5.2 Global RNA Interference (RNAi) Drug Delivery Revenue and Market Share by Application (2020-2025)

2.5.3 Global RNA Interference (RNAi) Drug Delivery Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global RNA Interference (RNAi) Drug Delivery Breakdown Data by Company

3.1.1 Global RNA Interference (RNAi) Drug Delivery Annual Sales by Company (2020-2025)

3.1.2 Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Company (2020-2025)

3.2 Global RNA Interference (RNAi) Drug Delivery Annual Revenue by Company (2020-2025)

3.2.1 Global RNA Interference (RNAi) Drug Delivery Revenue by Company (2020-2025)

3.2.2 Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Company (2020-2025)

3.3 Global RNA Interference (RNAi) Drug Delivery Sale Price by Company

3.4 Key Manufacturers RNA Interference (RNAi) Drug Delivery Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers RNA Interference (RNAi) Drug Delivery Product Location Distribution

3.4.2 Players RNA Interference (RNAi) Drug Delivery Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR RNA INTERFERENCE (RNAI) DRUG DELIVERY BY GEOGRAPHIC REGION

4.1 World Historic RNA Interference (RNAi) Drug Delivery Market Size by Geographic Region (2020-2025)

4.1.1 Global RNA Interference (RNAi) Drug Delivery Annual Sales by Geographic

Region (2020-2025)

4.1.2 Global RNA Interference (RNAi) Drug Delivery Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic RNA Interference (RNAi) Drug Delivery Market Size by Country/Region (2020-2025)

4.2.1 Global RNA Interference (RNAi) Drug Delivery Annual Sales by Country/Region (2020-2025)

4.2.2 Global RNA Interference (RNAi) Drug Delivery Annual Revenue by Country/Region (2020-2025)

4.3 Americas RNA Interference (RNAi) Drug Delivery Sales Growth

4.4 APAC RNA Interference (RNAi) Drug Delivery Sales Growth

4.5 Europe RNA Interference (RNAi) Drug Delivery Sales Growth

4.6 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales Growth

5 AMERICAS

5.1 Americas RNA Interference (RNAi) Drug Delivery Sales by Country

5.1.1 Americas RNA Interference (RNAi) Drug Delivery Sales by Country (2020-2025)

5.1.2 Americas RNA Interference (RNAi) Drug Delivery Revenue by Country (2020-2025)

5.2 Americas RNA Interference (RNAi) Drug Delivery Sales by Type (2020-2025)

5.3 Americas RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC RNA Interference (RNAi) Drug Delivery Sales by Region

6.1.1 APAC RNA Interference (RNAi) Drug Delivery Sales by Region (2020-2025)

6.1.2 APAC RNA Interference (RNAi) Drug Delivery Revenue by Region (2020-2025)

6.2 APAC RNA Interference (RNAi) Drug Delivery Sales by Type (2020-2025)

6.3 APAC RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe RNA Interference (RNAi) Drug Delivery by Country

7.1.1 Europe RNA Interference (RNAi) Drug Delivery Sales by Country (2020-2025)

7.1.2 Europe RNA Interference (RNAi) Drug Delivery Revenue by Country
(2020-2025)

7.2 Europe RNA Interference (RNAi) Drug Delivery Sales by Type (2020-2025)

7.3 Europe RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa RNA Interference (RNAi) Drug Delivery by Country

8.1.1 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Country
(2020-2025)

8.1.2 Middle East & Africa RNA Interference (RNAi) Drug Delivery Revenue by
Country (2020-2025)

8.2 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Type
(2020-2025)

8.3 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Application
(2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of RNA Interference (RNAi) Drug Delivery

10.3 Manufacturing Process Analysis of RNA Interference (RNAi) Drug Delivery

10.4 Industry Chain Structure of RNA Interference (RNAi) Drug Delivery

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 RNA Interference (RNAi) Drug Delivery Distributors

11.3 RNA Interference (RNAi) Drug Delivery Customer

12 WORLD FORECAST REVIEW FOR RNA INTERFERENCE (RNAI) DRUG DELIVERY BY GEOGRAPHIC REGION

12.1 Global RNA Interference (RNAi) Drug Delivery Market Size Forecast by Region

12.1.1 Global RNA Interference (RNAi) Drug Delivery Forecast by Region (2026-2031)

12.1.2 Global RNA Interference (RNAi) Drug Delivery Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global RNA Interference (RNAi) Drug Delivery Forecast by Type (2026-2031)

12.7 Global RNA Interference (RNAi) Drug Delivery Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Metabolic disorders

13.1.1 Metabolic disorders Company Information

13.1.2 Metabolic disorders RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

13.1.3 Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)

- 13.1.4 Metabolic disorders Main Business Overview
- 13.1.5 Metabolic disorders Latest Developments
- 13.2 Alnylam Pharmaceuticals Inc
 - 13.2.1 Alnylam Pharmaceuticals Inc Company Information
 - 13.2.2 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
 - 13.2.3 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.2.4 Alnylam Pharmaceuticals Inc Main Business Overview
 - 13.2.5 Alnylam Pharmaceuticals Inc Latest Developments
- 13.3 Merck & Co. Inc
 - 13.3.1 Merck & Co. Inc Company Information
 - 13.3.2 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
 - 13.3.3 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.3.4 Merck & Co. Inc Main Business Overview
 - 13.3.5 Merck & Co. Inc Latest Developments
- 13.4 Access Pharmaceuticals Inc
 - 13.4.1 Access Pharmaceuticals Inc Company Information
 - 13.4.2 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
 - 13.4.3 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.4.4 Access Pharmaceuticals Inc Main Business Overview
 - 13.4.5 Access Pharmaceuticals Inc Latest Developments
- 13.5 Dicerna Pharmaceuticals Inc
 - 13.5.1 Dicerna Pharmaceuticals Inc Company Information
 - 13.5.2 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
 - 13.5.3 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.5.4 Dicerna Pharmaceuticals Inc Main Business Overview
 - 13.5.5 Dicerna Pharmaceuticals Inc Latest Developments
- 13.6 Calondo Pharmaceuticals Inc
 - 13.6.1 Calondo Pharmaceuticals Inc Company Information
 - 13.6.2 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
 - 13.6.3 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales,

Revenue, Price and Gross Margin (2020-2025)

13.6.4 Calondo Pharmaceuticals Inc Main Business Overview

13.6.5 Calondo Pharmaceuticals Inc Latest Developments

13.7 Marina Biotech Inc

13.7.1 Marina Biotech Inc Company Information

13.7.2 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

13.7.3 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)

13.7.4 Marina Biotech Inc Main Business Overview

13.7.5 Marina Biotech Inc Latest Developments

13.8 RXi Pharmaceuticals Corp

13.8.1 RXi Pharmaceuticals Corp Company Information

13.8.2 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

13.8.3 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)

13.8.4 RXi Pharmaceuticals Corp Main Business Overview

13.8.5 RXi Pharmaceuticals Corp Latest Developments

13.9 Quark Pharmaceuticals Inc

13.9.1 Quark Pharmaceuticals Inc Company Information

13.9.2 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

13.9.3 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 Quark Pharmaceuticals Inc Main Business Overview

13.9.5 Quark Pharmaceuticals Inc Latest Developments

13.10 Silence Therapeutics plc

13.10.1 Silence Therapeutics plc Company Information

13.10.2 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

13.10.3 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)

13.10.4 Silence Therapeutics plc Main Business Overview

13.10.5 Silence Therapeutics plc Latest Developments

13.11 Tacere Therapeutics Inc

13.11.1 Tacere Therapeutics Inc Company Information

13.11.2 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

13.11.3 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)

13.11.4 Tacere Therapeutics Inc Main Business Overview

13.11.5 Tacere Therapeutics Inc Latest Developments

13.12 PhaseRx Inc

13.12.1 PhaseRx Inc Company Information

13.12.2 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

13.12.3 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)

13.12.4 PhaseRx Inc Main Business Overview

13.12.5 PhaseRx Inc Latest Developments

13.13 Sirnaomics Inc

13.13.1 Sirnaomics Inc Company Information

13.13.2 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

13.13.3 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)

13.13.4 Sirnaomics Inc Main Business Overview

13.13.5 Sirnaomics Inc Latest Developments

13.14 Traversa Therapeutics Inc

13.14.1 Traversa Therapeutics Inc Company Information

13.14.2 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

13.14.3 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)

13.14.4 Traversa Therapeutics Inc Main Business Overview

13.14.5 Traversa Therapeutics Inc Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. RNA Interference (RNAi) Drug Delivery Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. RNA Interference (RNAi) Drug Delivery Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of Nanoparticle Drug Delivery Technology

Table 4. Major Players of Pulmonary Drug Delivery Technology

Table 5. Major Players of Nucleic Acid Drug Delivery Technology

Table 6. Major Players of Aptamer Drug Delivery Technology

Table 7. Global RNA Interference (RNAi) Drug Delivery Sales by Type (2020-2025) & (K Units)

Table 8. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2020-2025)

Table 9. Global RNA Interference (RNAi) Drug Delivery Revenue by Type (2020-2025) & (\$ million)

Table 10. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Type (2020-2025)

Table 11. Global RNA Interference (RNAi) Drug Delivery Sale Price by Type (2020-2025) & (USD/Unit)

Table 12. Global RNA Interference (RNAi) Drug Delivery Sale by Application (2020-2025) & (K Units)

Table 13. Global RNA Interference (RNAi) Drug Delivery Sale Market Share by Application (2020-2025)

Table 14. Global RNA Interference (RNAi) Drug Delivery Revenue by Application (2020-2025) & (\$ million)

Table 15. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Application (2020-2025)

Table 16. Global RNA Interference (RNAi) Drug Delivery Sale Price by Application (2020-2025) & (USD/Unit)

Table 17. Global RNA Interference (RNAi) Drug Delivery Sales by Company (2020-2025) & (K Units)

Table 18. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Company (2020-2025)

Table 19. Global RNA Interference (RNAi) Drug Delivery Revenue by Company (2020-2025) & (\$ millions)

Table 20. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Company (2020-2025)

Table 21. Global RNA Interference (RNAi) Drug Delivery Sale Price by Company (2020-2025) & (USD/Unit)

Table 22. Key Manufacturers RNA Interference (RNAi) Drug Delivery Producing Area Distribution and Sales Area

Table 23. Players RNA Interference (RNAi) Drug Delivery Products Offered

Table 24. RNA Interference (RNAi) Drug Delivery Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global RNA Interference (RNAi) Drug Delivery Sales by Geographic Region (2020-2025) & (K Units)

Table 28. Global RNA Interference (RNAi) Drug Delivery Sales Market Share Geographic Region (2020-2025)

Table 29. Global RNA Interference (RNAi) Drug Delivery Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 30. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Geographic Region (2020-2025)

Table 31. Global RNA Interference (RNAi) Drug Delivery Sales by Country/Region (2020-2025) & (K Units)

Table 32. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Country/Region (2020-2025)

Table 33. Global RNA Interference (RNAi) Drug Delivery Revenue by Country/Region (2020-2025) & (\$ millions)

Table 34. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country/Region (2020-2025)

Table 35. Americas RNA Interference (RNAi) Drug Delivery Sales by Country (2020-2025) & (K Units)

Table 36. Americas RNA Interference (RNAi) Drug Delivery Sales Market Share by Country (2020-2025)

Table 37. Americas RNA Interference (RNAi) Drug Delivery Revenue by Country (2020-2025) & (\$ millions)

Table 38. Americas RNA Interference (RNAi) Drug Delivery Sales byType (2020-2025) & (K Units)

Table 39. Americas RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025) & (K Units)

Table 40. APAC RNA Interference (RNAi) Drug Delivery Sales by Region (2020-2025) & (K Units)

Table 41. APAC RNA Interference (RNAi) Drug Delivery Sales Market Share by Region (2020-2025)

Table 42. APAC RNA Interference (RNAi) Drug Delivery Revenue by Region (2020-2025) & (\$ millions)

Table 43. APAC RNA Interference (RNAi) Drug Delivery Sales byType (2020-2025) & (K Units)

Table 44. APAC RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025) & (K Units)

Table 45. Europe RNA Interference (RNAi) Drug Delivery Sales by Country (2020-2025) & (K Units)

Table 46. Europe RNA Interference (RNAi) Drug Delivery Revenue by Country (2020-2025) & (\$ millions)

Table 47. Europe RNA Interference (RNAi) Drug Delivery Sales byType (2020-2025) & (K Units)

Table 48. Europe RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025) & (K Units)

Table 49. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Country (2020-2025) & (K Units)

Table 50. Middle East & Africa RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2020-2025)

Table 51. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales byType (2020-2025) & (K Units)

Table 52. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of RNA Interference (RNAi) Drug Delivery

Table 54. Key Market Challenges & Risks of RNA Interference (RNAi) Drug Delivery

Table 55. Key IndustryTrends of RNA Interference (RNAi) Drug Delivery

Table 56. RNA Interference (RNAi) Drug Delivery Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. RNA Interference (RNAi) Drug Delivery Distributors List

Table 59. RNA Interference (RNAi) Drug Delivery Customer List

Table 60. Global RNA Interference (RNAi) Drug Delivery SalesForecast by Region (2026-2031) & (K Units)

Table 61. Global RNA Interference (RNAi) Drug Delivery RevenueForecast by Region (2026-2031) & (\$ millions)

Table 62. Americas RNA Interference (RNAi) Drug Delivery SalesForecast by Country (2026-2031) & (K Units)

Table 63. Americas RNA Interference (RNAi) Drug Delivery Annual RevenueForecast by Country (2026-2031) & (\$ millions)

Table 64. APAC RNA Interference (RNAi) Drug Delivery SalesForecast by Region (2026-2031) & (K Units)

Table 65. APAC RNA Interference (RNAi) Drug Delivery Annual RevenueForecast by Region (2026-2031) & (\$ millions)

Table 66. Europe RNA Interference (RNAi) Drug Delivery SalesForecast by Country (2026-2031) & (K Units)

Table 67. Europe RNA Interference (RNAi) Drug Delivery RevenueForecast by Country (2026-2031) & (\$ millions)

Table 68. Middle East & Africa RNA Interference (RNAi) Drug Delivery SalesForecast

by Country (2026-2031) & (K Units)

Table 69. Middle East & Africa RNA Interference (RNAi) Drug Delivery RevenueForecast by Country (2026-2031) & (\$ millions)

Table 70. Global RNA Interference (RNAi) Drug Delivery SalesForecast byType (2026-2031) & (K Units)

Table 71. Global RNA Interference (RNAi) Drug Delivery RevenueForecast byType (2026-2031) & (\$ millions)

Table 72. Global RNA Interference (RNAi) Drug Delivery SalesForecast by Application (2026-2031) & (K Units)

Table 73. Global RNA Interference (RNAi) Drug Delivery RevenueForecast by Application (2026-2031) & (\$ millions)

Table 74. Metabolic disorders Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 75. Metabolic disorders RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 76. Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 77. Metabolic disorders Main Business

Table 78. Metabolic disorders Latest Developments

Table 79. Alnylam Pharmaceuticals Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 80. Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 81. Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 82. Alnylam Pharmaceuticals Inc Main Business

Table 83. Alnylam Pharmaceuticals Inc Latest Developments

Table 84. Merck & Co. Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 85. Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 86. Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 87. Merck & Co. Inc Main Business

Table 88. Merck & Co. Inc Latest Developments

Table 89. Access Pharmaceuticals Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 90. Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 91. Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 92. Access Pharmaceuticals Inc Main Business

Table 93. Access Pharmaceuticals Inc Latest Developments

Table 94. Dicerna Pharmaceuticals Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 95. Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 96. Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 97. Dicerna Pharmaceuticals Inc Main Business

Table 98. Dicerna Pharmaceuticals Inc Latest Developments

Table 99. Calondo Pharmaceuticals Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 100. Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 101. Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 102. Calondo Pharmaceuticals Inc Main Business

Table 103. Calondo Pharmaceuticals Inc Latest Developments

Table 104. Marina Biotech Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 105. Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 106. Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 107. Marina Biotech Inc Main Business

Table 108. Marina Biotech Inc Latest Developments

Table 109. RXi Pharmaceuticals Corp Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 110. RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 111. RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 112. RXi Pharmaceuticals Corp Main Business

Table 113. RXi Pharmaceuticals Corp Latest Developments

Table 114. Quark Pharmaceuticals Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 115. Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product

Portfolios and Specifications

Table 116. Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 117. Quark Pharmaceuticals Inc Main Business

Table 118. Quark Pharmaceuticals Inc Latest Developments

Table 119. SilenceTherapeutics plc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 120. SilenceTherapeutics plc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 121. SilenceTherapeutics plc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 122. SilenceTherapeutics plc Main Business

Table 123. SilenceTherapeutics plc Latest Developments

Table 124. TacereTherapeutics Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 125. TacereTherapeutics Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 126. TacereTherapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 127. TacereTherapeutics Inc Main Business

Table 128. TacereTherapeutics Inc Latest Developments

Table 129. PhaseRx Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 130. PhaseRx Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 131. PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 132. PhaseRx Inc Main Business

Table 133. PhaseRx Inc Latest Developments

Table 134. Sirnaomics Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 135. Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 136. Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 137. Sirnaomics Inc Main Business

Table 138. Sirnaomics Inc Latest Developments

Table 139. TraversaTherapeutics Inc Basic Information, RNA Interference (RNAi) Drug Delivery Manufacturing Base, Sales Area and Its Competitors

Table 140.TraversaTherapeutics Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications

Table 141.TraversaTherapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 142.TraversaTherapeutics Inc Main Business

Table 143.TraversaTherapeutics Inc Latest Developments

LIST OFFIGURES

Figure 1. Picture of RNA Interference (RNAi) Drug Delivery

Figure 2. RNA Interference (RNAi) Drug Delivery Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global RNA Interference (RNAi) Drug Delivery Sales Growth Rate 2020-2031 (K Units)

Figure 7. Global RNA Interference (RNAi) Drug Delivery Revenue Growth Rate 2020-2031 (\$ millions)

Figure 8. RNA Interference (RNAi) Drug Delivery Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Figure 9. RNA Interference (RNAi) Drug Delivery Sales Market Share by Country/Region (2024)

Figure 10. RNA Interference (RNAi) Drug Delivery Sales Market Share by Country/Region (2020, 2024 & 2031)

Figure 11. Product Picture of Nanoparticle Drug DeliveryTechnology

Figure 12. Product Picture of Pulmonary Drug DeliveryTechnology

Figure 13. Product Picture of Nucleic Acid Drug DeliveryTechnology

Figure 14. Product Picture of Aptamer Drug DeliveryTechnology

Figure 15. Global RNA Interference (RNAi) Drug Delivery Sales Market Share byType in 2025

Figure 16. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share byType (2020-2025)

Figure 17. RNA Interference (RNAi) Drug Delivery Consumed in Infectious Diseases

Figure 18. Global RNA Interference (RNAi) Drug Delivery Market: Infectious Diseases (2020-2025) & (K Units)

Figure 19. RNA Interference (RNAi) Drug Delivery Consumed in Cardiology

Figure 20. Global RNA Interference (RNAi) Drug Delivery Market: Cardiology

(2020-2025) & (K Units)

Figure 21. RNA Interference (RNAi) Drug Delivery Consumed in Oncology

Figure 22. Global RNA Interference (RNAi) Drug Delivery Market: Oncology
(2020-2025) & (K Units)

Figure 23. RNA Interference (RNAi) Drug Delivery Consumed in Neurology

Figure 24. Global RNA Interference (RNAi) Drug Delivery Market: Neurology
(2020-2025) & (K Units)

Figure 25. RNA Interference (RNAi) Drug Delivery Consumed in Ophthalmology

Figure 26. Global RNA Interference (RNAi) Drug Delivery Market: Ophthalmology
(2020-2025) & (K Units)

Figure 27. RNA Interference (RNAi) Drug Delivery Consumed in Metabolic Disorders

Figure 28. Global RNA Interference (RNAi) Drug Delivery Market: Metabolic Disorders
(2020-2025) & (K Units)

Figure 29. Global RNA Interference (RNAi) Drug Delivery Sale Market Share by
Application (2024)

Figure 30. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by
Application in 2025

Figure 31. RNA Interference (RNAi) Drug Delivery Sales by Company in 2025 (K Units)

Figure 32. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by
Company in 2025

Figure 33. RNA Interference (RNAi) Drug Delivery Revenue by Company in 2025 (\$
millions)

Figure 34. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by
Company in 2025

Figure 35. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by
Geographic Region (2020-2025)

Figure 36. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by
Geographic Region in 2025

Figure 37. Americas RNA Interference (RNAi) Drug Delivery Sales 2020-2025 (K Units)

Figure 38. Americas RNA Interference (RNAi) Drug Delivery Revenue 2020-2025 (\$
millions)

Figure 39. APAC RNA Interference (RNAi) Drug Delivery Sales 2020-2025 (K Units)

Figure 40. APAC RNA Interference (RNAi) Drug Delivery Revenue 2020-2025 (\$
millions)

Figure 41. Europe RNA Interference (RNAi) Drug Delivery Sales 2020-2025 (K Units)

Figure 42. Europe RNA Interference (RNAi) Drug Delivery Revenue 2020-2025 (\$
millions)

Figure 43. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales
2020-2025 (K Units)

Figure 44. Middle East & Africa RNA Interference (RNAi) Drug Delivery Revenue 2020-2025 (\$ millions)

Figure 45. Americas RNA Interference (RNAi) Drug Delivery Sales Market Share by Country in 2025

Figure 46. Americas RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2020-2025)

Figure 47. Americas RNA Interference (RNAi) Drug Delivery Sales Market Share byType (2020-2025)

Figure 48. Americas RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2020-2025)

Figure 49. United States RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 50. Canada RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 51. Mexico RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 52. Brazil RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 53. APAC RNA Interference (RNAi) Drug Delivery Sales Market Share by Region in 2025

Figure 54. APAC RNA Interference (RNAi) Drug Delivery Revenue Market Share by Region (2020-2025)

Figure 55. APAC RNA Interference (RNAi) Drug Delivery Sales Market Share byType (2020-2025)

Figure 56. APAC RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2020-2025)

Figure 57. China RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 58. Japan RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 59. South Korea RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 60. Southeast Asia RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 61. India RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 62. Australia RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 63. ChinaTaiwan RNA Interference (RNAi) Drug Delivery Revenue Growth

2020-2025 (\$ millions)

Figure 64. Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Country in 2025

Figure 65. Europe RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2020-2025)

Figure 66. Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2020-2025)

Figure 67. Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2020-2025)

Figure 68. Germany RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 69. France RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 70. UK RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 71. Italy RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 72. Russia RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 73. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Country (2020-2025)

Figure 74. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2020-2025)

Figure 75. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2020-2025)

Figure 76. Egypt RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 77. South Africa RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 78. Israel RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 79. Turkey RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 80. GCC Countries RNA Interference (RNAi) Drug Delivery Revenue Growth 2020-2025 (\$ millions)

Figure 81. Manufacturing Cost Structure Analysis of RNA Interference (RNAi) Drug Delivery in 2025

Figure 82. Manufacturing Process Analysis of RNA Interference (RNAi) Drug Delivery

Figure 83. Industry Chain Structure of RNA Interference (RNAi) Drug Delivery

Figure 84. Channels of Distribution

Figure 85. Global RNA Interference (RNAi) Drug Delivery Sales MarketForecast by Region (2026-2031)

Figure 86. Global RNA Interference (RNAi) Drug Delivery Revenue Market ShareForecast by Region (2026-2031)

Figure 87. Global RNA Interference (RNAi) Drug Delivery Sales Market ShareForecast byType (2026-2031)

Figure 88. Global RNA Interference (RNAi) Drug Delivery Revenue Market ShareForecast byType (2026-2031)

Figure 89. Global RNA Interference (RNAi) Drug Delivery Sales Market ShareForecast by Application (2026-2031)

Figure 90. Global RNA Interference (RNAi) Drug Delivery Revenue Market ShareForecast by Application (2026-2031)

I would like to order

Product name: Global RNA Interference (RNAi) Drug Delivery Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G48FF7A28B67EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G48FF7A28B67EN.html>